Full Text View
Tabular View
No Study Results Posted
Related Studies
Prevention of Radiation Pneumonitis After Three-Dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-Small-Cell Lung Cancer
This study is currently recruiting participants.
Study NCT00349102   Information provided by Centre Leon Berard
First Received: July 5, 2006   Last Updated: June 23, 2009   History of Changes

July 5, 2006
June 23, 2009
July 2006
July 2013   (final data collection date for primary outcome measure)
Clinical, functional and radiological evaluations at 6-8 weeks and 10-12 weeks after the end of irradiation [ Time Frame: 6-8 and 10-12 weeks after the end of irradiation ] [ Designated as safety issue: No ]
Clinical, functional and radiological evaluations at 6-8 weeks and 10-12 weeks after the end of irradiation
Complete list of historical versions of study NCT00349102 on ClinicalTrials.gov Archive Site
RTOG and LENT-SOMA scores at 6-8 weeks and 10-12 weeks after the end of irradiation, response rates at 6-8 weeks, 1 year and 2 years after irradiation [ Time Frame: 6-8 and 10-12 weeks after the end of irradiation ] [ Designated as safety issue: No ]
RTOG and LENT-SOMA scores at 6-8 weeks and 10-12 weeks after the end of irradiation, response rates at 6-8 weeks, 1 year and 2 years after irradiation
 
Prevention of Radiation Pneumonitis After Three-Dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-Small-Cell Lung Cancer
Evaluation of the Interest of Breath Holding for the Prevention of Radiation Pneumonitis Following Conformal Radiation Therapy

The purpose of this study is to evaluate the interest of breath holding for the prevention of radiation pneumonitis following conformal radiation therapy.

Eligible patients will be randomly assigned in a 2-arm trial to free breathing or breath holding during conformal radiation.

The primary objective of the study is to establish the efficacy of breath holding, compared to free breathing, in the prevention of early pulmonary toxicity following conformal radiation.

Several departments of radiotherapy, many pneumology units and two basic and applied research laboratories take part in this multicentric study.

The number of patients required to demonstrate a reduction in radiation pneumonitis from 45 % to 22.5 %, assuming an alpha risk of 5% in a two-sided test and 95% power, is 240 (120 per arm). With a planned accrual of 7 patients per month, it is estimated that the inclusion period should be approximately 3 years.

The secondary objectives are:

  • Validation of the Lent-Soma toxicity scale by comparison to the RTOG scale,
  • Response rate at different times: week 6-8, 1 year and 2 years after the end of irradiation,
  • Progression-free survival rate at 1 year and 2 years after the end of irradiation
  • Confirmation of the predictive value of serum cytokine levels (IL-6 and IL-10) during irradiation for the occurrence of early radiation toxicity, and analysis of the correlation between these serum levels at inclusion and the expression polymorphism of candidate genes.
Phase III
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Carcinoma, Non-Small-Cell Lung
  • Radiation: Free breathing
  • Radiation: Breath holding
  • Active Comparator: Free breathing during conformal radiation
  • Experimental: Breath holding during conformal radiation

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
240
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Non-metastatic cytologically or histologically proven non-small-cell lung cancer (NSCLC)
  • Operated NSCLC patients requiring post-surgical irradiation or non-operated NSCLC patients requiring curative irradiation
  • Conformational thoracic radiotherapy with curative intent
  • Age >= 18
  • Complete functional respiratory evaluation (FRE) performed less than 2 months before inclusion, demonstrating a maximum expiratory flow-volume/second > 1 l (in case surgery, the FRE must have been realized in the post-surgery period)
  • Thoracic CT-scan performed less than 2 months before inclusion for non-operated patient
  • PET-scan performed less than 2 months before inclusion for non-operated patient
  • Performance status (PS) ECOG <= 1
  • Possible training on breath holding technique
  • Female patients of childbearing potential: effective method of contraception necessary
  • Mandatory affiliation with a social security system
  • Written, signed, informed consent

Exclusion Criteria:

  • Small-cell lung cancer
  • Metastatic disease
  • Infiltrating pulmonary disease
  • Previous thoracic irradiation
  • Indication of irradiation with palliative intent
  • Previous or concurrent primary malignancies at other sites (except basocellular skin cancer or cervical cancer in situ or complete remission for more than 5 years)
  • Life expectancy < 6 months
  • Patient understanding incompatible with the breath-hold technique (patients with major presbycusis are not eligible)
  • Pregnant or lactating woman
  • Patient included in another clinical trial
  • Follow-up difficult
  • Patient deprived of freedom
Both
18 Years and older
No
Contact: Sophie DUSSART, MD +33 478 78 27 52 dussart@lyon.fnclcc.fr
Contact: Severine GUILLEMAUT +33 478 78 29 68 denizot@lyon.fnclcc.fr
France
 
NCT00349102
Zora ABDELBOST, Centre Léon Bérard, 28 rue Laënnec, 69373 LYON Cedex 08, FRANCE
GATING 2006, ET2005-052
Centre Leon Berard
Ministry of Health, France
Principal Investigator: Line CLAUDE, MD Centre Leon Berard, Lyon
Centre Leon Berard
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP